Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
Program Halt Seen As 'Hit' To Vaccine-Making Reputation
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
